Study #2017-0319
Serial Imaging of the Novel Radiotracer 18F FLuorthanatrace (18F, FTT) by PET/CT
MD Anderson Study Status
Enrolling
Treatment Agent
Description
This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET/CT uses a scanner to make detailed, computerized pictures of areas inside the body. PET/CT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Carcinoma;Fallopian Tube Carcinoma;Ovarian Carcinoma;Primary Peritoneal Carcinoma;Recurrent Fallopian Tube Carcinoma;Recurrent Ovarian Carcinoma;Recurrent Primary Peritoneal Carcinoma;Solid Neoplasm
Study phase:
Phase I
Physician name:
Lilie Lin
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.